{"id":"W1803778850","doi":"10.1002/ana.24339","title":"Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis","year":2014,"lang":"en","type":"article","venue":"Annals of Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne; Hôpital Notre-Dame; Cégep de Lévis","funders":"National Health and Medical Research Council; EMD Serono; Canadian Institutes of Health Research; Multiple Sclerosis Australia; Teva Pharmaceutical Industries; Novartis Pharma; Multiple Sclerosis Society; Biogen; Sanofi","keywords":"Fingolimod; Natalizumab; Medicine; Multiple sclerosis; Glatiramer acetate; Internal medicine; Propensity score matching; Hazard ratio; Cohort; Expanded Disability Status Scale; Randomized controlled trial; Physical therapy; Confidence interval; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0005175904,0.0001902366,0.0005665322,0.0004038904,0.00007531114,0.000007559903,0.0002065491,0.0001457393,0.00003261152],"category_scores_gemma":[0.009277346,0.0001822816,0.0001175158,0.000446637,0.0001433999,0.00008038961,0.0002939262,0.0004435845,0.00004569686],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002013068,"about_ca_system_score_gemma":0.00004549449,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004931127,"about_ca_topic_score_gemma":0.000352697,"domain_scores_codex":[0.9978791,0.0002311966,0.000412907,0.000489375,0.0003574208,0.0006299655],"domain_scores_gemma":[0.9974036,0.001560279,0.000124797,0.0004419388,0.0002747111,0.0001946965],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.04998477,0.001709685,0.2186867,0.0005083819,0.0006023412,0.0001167377,0.006133069,0.001153857,0.3405223,0.0007043322,0.01671134,0.3631665],"study_design_scores_gemma":[0.00541279,0.003276375,0.9476651,0.000162321,0.0000161735,0.000007766525,0.00009773047,0.002072358,0.03435159,0.00004888545,0.006711466,0.0001774664],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9778677,0.00007317685,0.00003851447,0.01854682,0.0002385646,0.0004078418,0.00001190751,0.00004281029,0.002772677],"genre_scores_gemma":[0.9963933,0.0002357638,0.0003083483,0.002803099,0.0001381531,0.00004959157,0.000006753694,0.00003161675,0.00003341752],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7289784,"threshold_uncertainty_score":0.9990679,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2028620345828532,"score_gpt":0.3749256953309814,"score_spread":0.1720636607481283,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}